APUS · Categories · Form 4

APUS - SEC Form 4 insider transactions

Apimeds Pharmaceuticals US Inc. (APUS) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.

Recent Form 4 for APUS

• 156d
  Amendment: SEC Form 4 filed by Large owner Inscobee Inc.

  4/A - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
• 164d
  SEC Form 4 filed by Director Weintraub Bennett

  4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
• 164d
  SEC Form 4 filed by Director Yoon Hankil

  4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
• 164d
  SEC Form 4 filed by Director Koo Jakap

  4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
• 164d
  SEC Form 4 filed by Director O'Donnell Carol A

  4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
• 164d
  SEC Form 4 filed by Director Kogan Elona

  4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
• 184d
  SEC Form 4 filed by Director Kogan Elona

  4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
• 187d
  SEC Form 4 filed by Director O'Donnell Carol A

  4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
• 191d
  SEC Form 4 filed by Director Koo Jakap

  4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
• 191d
  SEC Form 4 filed by Director Weintraub Bennett

  4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
• 191d
  SEC Form 4 filed by Chairman and CMO Kim Christopher

  4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
• 191d
  SEC Form 4 filed by Director Yoon Hankil

  4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
• 191d
  SEC Form 4 filed by Chief Executive Officer Emerson Erik C.

  4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
• 319d
  Amendment: Large owner Inscobee Inc. converted options into 115,131 shares, increasing direct ownership by 6% to 2,099,747 units (SEC Form 4)

  4/A - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
• 341d
  SEC Form 4 filed by Director Kogan Elona

  4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
• 341d
  SEC Form 4 filed by Director Yoon Hankil

  4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
• 341d
  SEC Form 4 filed by Director O'Donnell Carol A

  4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
• 341d
  Chairman and CMO Kim Christopher was granted 250,000 shares, increasing direct ownership by 909% to 277,500 units (SEC Form 4)

  4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
• 341d
  Chief Executive Officer Emerson Erik C. was granted 750,000 shares (SEC Form 4)

  4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
• 341d
  SEC Form 4 filed by Director Weintraub Bennett

  4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
• 341d
  SEC Form 4 filed by Director Koo Jakap

  4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)

Other APUS categories

• 8-K
• 10-K
• 10-Q
• S-1
• 13D
• 13G
• Form 3
• Form 5
• DEF 14A
• M&A
• Earnings
• Dividends